Monaco Lab
Effect of the Microbiome/Virome on Mucosal and Systemic Inflammation in Health and Disease
We study the bacterial and viral microbiome at mucosal surfaces to determine how these organisms contribute to inflammation and disease states. The human microbiome consists of bacteria and archaea, viruses and bacteriophage, fungi, protists, and other microbial eukaryotes. Composition of the microbiota varies by body site and is unique between individuals. The relatively low sequencing cost associated with 16S rRNA genomics and publically available tools for demultiplexing, quality control, bacterial sequence identification has facilitated bacteriome exploration. Research into the virome has been hampered by lack of a common genetic element to enable a “pan-virus” PCR and difficulty culturing many viruses. Next generation sequencing has revolutionized the study of this important microbial compartment. Using next-generation sequencing, molecular biology techniques and bioinformatics analysis we are exploring the contributions of the human microbiome and virome on health and disease.
One of the focuses of our laboratory is HIV (Human Immunodeficiency virus). HIV constitutes a serious public health problem with an estimated 1.1 million adults infected in the United States alone, and approximately 50,000 new infections annually. HIV enters through mucosal membranes and rapidly targets the CD4+ T cell population, leading to disruption of immune homeostasis, induction of inflammatory cytokines and chemokines, and eventually if untreated the development of opportunistic infections and death. Antiretroviral therapy (ART) successfully controls replicating virus populations, but immune recovery is variable making preventative or curative strategies imperative. We have previously shown that immunodeficiency from HIV infection is associated with alterations in enteric bacterial diversity and expansion of potentially pathogenic enteric bacteria and viruses. Treatment of mucosal pathogens, in conjunction with ART, may minimize HIV-associated chronic immune activation and decrease morbidity and mortality in persons living with HIV.
Cynthia Monaco, M.D., Ph.D.
Principal Investigator
- Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.; Journal of acquired immune deficiency syndromes (1999); Vol 96(4), pp. 350-360. 2024 Jun 21.
- SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.; JAMA network open; Vol 7(5), pp. e2412835. 2024 May 01.
- Gut microbiome in the first 1000 days and risk for childhood food allergy.; Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2024 Mar 15.
- Risk of COVID-19 after natural infection or vaccination.; EBioMedicine; Vol 96, pp. 104799. 2023 Sep 20.
Contact Us
Monaco Lab
601 Elmwood Ave, MRBX, 2.11301
Rochester, NY 14642